About AbbVie Inc.
Pharma cash-flow engine built on Skyrizi/Rinvoq immunology, Botox aesthetics, and a declining Humira franchise. Dividend King with ~3% yield and 52+ consecutive annual increases. Very low beta (~0.33) keeps premiums cheap for put sellers, though FDA decisions and pipeline readouts inject occasional binary risk.
Pharmaceuticals